CVS has agreed to pay $315 million to resolve federal allegations of unlawful controlled substance dispensing and improper Medicare billing, underscoring ongoing enforcement of pharmacy compliance requirements under the Controlled Substances...
CVS has agreed to pay $315 million to resolve federal allegations of unlawful controlled substance dispensing and improper Medicare billing, underscoring ongoing enforcement of pharmacy compliance requirements under the Controlled Substances...
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
Florida is challenging insulin manufacturer and pharmacy benefit manager (PBM) rebate and formulary arrangements that the state alleges contributed to higher insulin costs and restricted competition.
Florida is challenging insulin manufacturer and pharmacy benefit manager (PBM) rebate and formulary arrangements that the state alleges contributed to higher insulin costs and restricted competition.
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Walmart has agreed to pay $50 million to resolve federal allegations that its pharmacies unlawfully filled thousands of opioid and other controlled substance prescriptions.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
Monogram Health has agreed to pay $2.4 million to settle federal allegations that unsupported diagnosis codes led to increased Medicare Advantage payments.
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
AstraZeneca has joined AbbVie and Novartis in challenging Illinois’ new 340B contract pharmacy law, adding to a growing national legal battle over state authority to regulate manufacturer distribution requirements and compliance data within...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
Eli Lilly has filed 6 lawsuits against companies allegedly selling unapproved versions of investigational obesity drug retatrutide, highlighting growing legal and regulatory scrutiny of unauthorized products entering the rapidly expanding...
BioSpectra voluntarily recalled 200 kg of tris/tromethamine after the product failed to meet stability specifications, prompting a Class II classification by the FDA.
BioSpectra voluntarily recalled 200 kg of tris/tromethamine after the product failed to meet stability specifications, prompting a Class II classification by the FDA.
A voluntary Class II recall has been issued for fosfomycin tromethamine granules for oral solution due to the product’s failure to meet impurities specifications.
A voluntary Class II recall has been issued for fosfomycin tromethamine granules for oral solution due to the product’s failure to meet impurities specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for IMAAVY (nipocalimab-aahu) injection due to the presence of particulate matter, affecting 49 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for IMAAVY (nipocalimab-aahu) injection due to the presence of particulate matter, affecting 49 vials.
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
A voluntary Class II recall has been issued for Menow sunscreen pressed powder due to Current Good Manufacturing Practice (CGMP) deviations, a discrepancy that affects 2970 units.
A voluntary Class II recall has been issued for Menow sunscreen pressed powder due to Current Good Manufacturing Practice (CGMP) deviations, a discrepancy that affects 2970 units.
The US Food and Drug Administration (FDA) has issued a Class II recall for exenatide injection due to a defective drug delivery system, affecting 5694 pens.
The US Food and Drug Administration (FDA) has issued a Class II recall for exenatide injection due to a defective drug delivery system, affecting 5694 pens.
BioSpectra voluntarily recalled 200 kg of tris/tromethamine after the product failed to meet stability specifications, prompting a Class II classification by the FDA.
BioSpectra voluntarily recalled 200 kg of tris/tromethamine after the product failed to meet stability specifications, prompting a Class II classification by the FDA.
A voluntary Class II recall has been issued for fosfomycin tromethamine granules for oral solution due to the product’s failure to meet impurities specifications.
A voluntary Class II recall has been issued for fosfomycin tromethamine granules for oral solution due to the product’s failure to meet impurities specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for IMAAVY (nipocalimab-aahu) injection due to the presence of particulate matter, affecting 49 vials.
The US Food and Drug Administration (FDA) has issued a Class II recall for IMAAVY (nipocalimab-aahu) injection due to the presence of particulate matter, affecting 49 vials.
CVS has agreed to pay $315 million to resolve federal allegations of unlawful controlled substance dispensing and improper Medicare billing, underscoring ongoing enforcement of pharmacy compliance requirements under the Controlled Substances...
CVS has agreed to pay $315 million to resolve federal allegations of unlawful controlled substance dispensing and improper Medicare billing, underscoring ongoing enforcement of pharmacy compliance requirements under the Controlled Substances...
